key: cord-0920018-c1q3203f authors: Pal, Rimesh; Bhadada, Sanjay K. title: Managing common endocrine disorders amid COVID-19 pandemic date: 2020-06-04 journal: Diabetes Metab Syndr DOI: 10.1016/j.dsx.2020.05.050 sha: bd9fa139f78266896f76293b606ac4fe2ec5c57e doc_id: 920018 cord_uid: c1q3203f BACKGROUND AND AIMS: The novel coronavirus disease (COVID-19) pandemic and the resulting nationwide lockdowns have posed a major challenge to the management of pre-existing and newly diagnosed endocrine disorders. Herein, we have summarized the management approaches of common endocrine disorders amid the ongoing pandemic. METHODS: We have performed an extensive literature search for articles in PubMed, EMBASE and Google Scholar databases till 25 May 2020, with the following keywords: “COVID-19”, “diabetes mellitus”, “thyroid disorders”, “primary adrenal insufficiency”, “Cushing's syndrome”, “pituitary tumors”, “vitamin D″, “osteoporosis”, “primary hyperparathyroidism”, “hypoparathyroidism”, “management”, “treatment” and “guidelines” with interposition of the Boolean operator “AND”. RESULTS: We have summarized the feasible strategies for the management of diabetes mellitus, hypothyroidism, hyperthyroidism, primary adrenal insufficiency (including congenital adrenal hyperplasia), Cushing's syndrome, pituitary tumors, osteoporosis, primary hyperparathyroidism and hypoparathyroidism amid the constraints laid down by the raging pandemic. In general, medical management should be encouraged and surgical interventions should be deferred whenever possible. Ongoing medications should be continued. Sick-day rules should be sincerely adhered to. Regular contact with physicians can be maintained through teleconsultations and virtual clinics. CONCLUSIONS: Considering the burden of endocrine disorders in the general population, their management needs to be prioritized amid the ongoing COVID-19 pandemic. • The COVID-19 pandemic has posed a challenge to the management of common endocrine disorders. • Medical management should be preferred over surgery whenever feasible. • Ongoing medications should be continued and sick-day guidelines should be strictly followed. 3 The novel coronavirus disease pandemic and the resulting nationwide lockdowns have posed a major challenge to the management of pre-existing and newly diagnosed endocrine disorders. Herein, we have summarized the management approaches of common endocrine disorders amid the ongoing pandemic. We have performed an extensive literature search for articles in PubMed, EMBASE and Google Scholar databases till 25 May 2020, with the following keywords: "COVID-19", "diabetes mellitus", "thyroid disorders", "primary adrenal insufficiency", "Cushing's syndrome", "pituitary tumors", "vitamin D", "osteoporosis", "primary hyperparathyroidism", "hypoparathyroidism", "management", "treatment" and "guidelines" with interposition of the Boolean operator "AND". We have summarized the feasible strategies for the management of diabetes mellitus, hypothyroidism, hyperthyroidism, primary adrenal insufficiency (including congenital adrenal hyperplasia), Cushing's syndrome, pituitary tumors, osteoporosis, primary hyperparathyroidism and hypoparathyroidism amid the constraints laid down by the raging pandemic. In general, medical management should be encouraged and surgical interventions should be deferred whenever possible. Ongoing medications should be continued. Sick-day rules should be sincerely adhered to. Regular contact with physicians can be maintained through teleconsultations and virtual clinics. The novel coronavirus disease (COVID -19) has been on the rampage ever since its outbreak in December 2019 in Wuhan, China. Till date, the disease has affected over 5.3 million people, inflicting more than 342000 casualties in over 200 nations worldwide (1) . In the absence of any effective vaccine or therapy against SARS-CoV-2, social distancing, hand hygiene and community containment seems to be the most People with diabetes mellitus are at a high risk of severe disease, acute respiratory distress syndrome and increased mortality due to COVID-19 (5, 6) . Good glycemic control is expected to strengthen the innate immune system and help ward off these complications (7) . However, limitation of physical activity, altered diet, restricted availability of anti-diabetic medications and lack of in-clinic follow-ups as a result of the ongoing pandemic is expected to adversely affect the glycemic control (8) prophylaxis of COVID-19, it could be a good add-on anti-diabetic drug (7, 9) . Although not FDA certified, the drug has been used as an anti-diabetic medication and is approved by the Drug Controller General of India as a third-line drug after metformin and sulfonylureas. The drug acts by raising intracellular pH that inhibits proteolytic degradation of insulin, resulting in recirculation of insulin in its active form. Hydroxychloroquine also reduces pro-inflammatory cytokines, notably TNFα and IL6, thereby reducing insulin resistance (10) . Considering its low-cost, moderate efficacy and once daily dosing, hydroxychloroquine might hold a good potential for use as an add-on drug in patients with poor glycemic control amid the ongoing pandemic, especially in countries with a poor socioeconomic background (7). Self-monitoring of capillary blood glucose, especially for patients on insulin, should be continued at home and appropriate teleconsultations should be sought during recurrent episodes of hyperglycemia or hypoglycemia (11, 12) . Patients with type 1 diabetes mellitus should be kept thoroughly informed about sick-day guidelines and that omission of insulin could be fatal. Often neglected is the psychological wellbeing of patients with DM which is likely to be adversely affected in current times. Meditations, teleconsultations with psychiatrists and avoiding undue stress by intentionally minimizing watching, reading or listening to news about COVID-19 could be helpful (8) . Patients with thyroid disorders are frequently encountered in an endocrinology outpatient clinic. Although there is no evidence that patients with poorly controlled thyroid disease are more likely to contract viral infection in general, it is possible that patients with uncontrolled hyperthyroidism may be at a higher risk of complications (like thyroid storm) precipitated by any infection. In general, patients with underlying hypothyroidism or hyperthyroidism should continue their medications as usual. The usual advice of increasing the dose of levothyroxine during pregnancy should be adhered to. Management of hyperthyroidism usually requires frequent monitoring of thyroid function test. If biochemical monitoring cannot be performed due to prevailing circumstances, a block-and-replace regimen may be followed, especially after teleconsultation with an experienced endocrinologist. Block-and-replace regimen would be most ideal for newly diagnosed patients with hyperthyroidism (13) . The use of anti-thyroid drugs (ATDs) demands a special mention. Use of ATDs is associated with the risk of agranulocytosis, albeit rarely; agranulocytosis in turn may increase the risk of progression of COVID-19 (13) . Symptoms of agranulocytosis (fever, sore throat, oral ulcers) often overlap with those of mild COVID-19 (fever, cough, headache), hence, often making it difficult to clinically differentiate one from the other (13, 14) . In the unlikely event that a patient on ATD develops symptoms suggestive of agranulocytosis, the ATD should be immediately stopped and an urgent full blood count should be performed. If a blood count cannot be performed due to severe limitation of healthcare resources, the ATD can be stopped and restarted after 1 week if symptoms resolve (14) . In selected cases of uncontrolled thyrotoxicosis not responding to medical management, urgent surgery or radioactive iodine ablation may be undertaken. In addition, patients with COVID-19 presenting with conjunctivitis may cause diagnostic difficulties in those with new-onset or existing thyroidassociated orbitopathy (TAO) (13) . On the other hand, patients with TAO on glucocorticoids and/or mycophenolate mofetil are likely to be immunocompromised and need to take extra precautions against COVID-19. Similarly, patients with metastatic thyroid cancer might be at an increased risk of viral infection or complications if they have lung metastasis and hence need to be more cautious (15) . Patients with primary adrenal insufficiency including Addison's disease and congenital adrenal hyperplasia are at an increased risk of infections (16, 17) . Patients with PAI exhibit an inefficient innate immune response, characterized by decreased cytotoxic natural killer cells, with secondary failure of IgG-mediated activation due to shedding of CD16, its surface receptor (18) . Therefore, PAI can be assumed to increase the risk of infection with COVID-19 (19) . In addition, stress-induced rise in serum cortisol plays an important role in priming the immune system; expectedly, lack of cortisol rise in patients with PAI might predispose them to higher risk of progression to critical stages (20, 21 (27) . Hitherto, there is currently no proven concern that pituitary tumors per se affect (39) . Patients with hypoparathyroidism should continue calcium/active vitamin D supplements. In addition, they should be made conversant with the sick-day guidelines, specially the need to double the dose of calcium/vitamin D during periods 17 of stressful situations. The relevance lies in the fact that any acute illness and even anxiety (as is prevalent amid the ongoing pandemic) can lead to hyperventilation, respiratory alkalosis and subsequently reduce serum ionized calcium (40) . The COVID-19) Situation Report -126 Global and regional diabetes prevalence estimates for Global epidemiology of hyperthyroidism and hypothyroidism Facts and Statistics | International Osteoporosis Foundation COVID-19, Diabetes Mellitus and ACE2: The conundrum COVID-19 and diabetes mellitus: An unholy interaction of two pandemics Should anti-diabetic medications be reconsidered amid COVID-19 pandemic? Diabetes self-management amid COVID-19 pandemic Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations Effect of early addition of hydroxychloroquine in type 2 diabetic patients inadequately controlled on metformin and sulfonylurea combination therapy Telemedicine for diabetes care in India during COVID19 pandemic and national lockdown period: Guidelines for physicians Teleconsultation and Diabetes Care Amid COVID-19 Pandemic in India: Scopes and Challenges Endocrinology in the time of COVID-19: Management of hyper-and hypo-thyroidism BTA/SFE statement regarding issues specific to thyroid dysfunction during the COVID -19 pandemic AACE Position Statement: Coronavirus (COVID-19) and People with Thyroid Disease Increased Infection Risk in Addison's Disease and Congenital Adrenal Hyperplasia Increased use of antimicrobial agents and hospital admission for infections in patients with primary adrenal insufficiency: a cohort study Effect of once-daily, modified-release hydrocortisone versus standard glucocorticoid therapy on metabolism and innate immunity in patients with adrenal insufficiency (DREAM): a single-blind, randomised controlled trial Endocrinology in the time of COVID-19: Management of adrenal insufficiency COVID-19 infection and glucocorticoids: update from the Italian Society of Endocrinology Expert Opinion on steroid replacement in adrenal insufficiency Adrenal function and dysfunction in critically ill patients AACE Position Statement: Coronavirus (COVID-19) and People with Adrenal Insufficiency and Cushing's Syndrome Endocrinology in the time of COVID-19: Management of Cushing's syndrome Pal R, Bhadada SK. COVID-19 and non-communicable diseases Letter: Precautions for Endoscopic Transnasal Skull Base Surgery During the COVID-19 Pandemic Hepatic safety of ketoconazole in Cushing's syndrome: results of a Compassionate Use Programme in France Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline Exploring Inpatient Hospitalizations and Morbidity in Patients With Adrenal Insufficiency Our Response to COVID-19 as Endocrinologists and Diabetologists Endocrinology in the time of COVID-19: Management of pituitary tumours Vitamin-D and COVID-19: do deficient risk a poorer outcome? Lancet Diabetes Endocrinol Perspective: improving vitamin D status in the management of COVID-19 Angiotensin-converting enzyme 2 protects from severe acute lung failure High-Intensity Resistance and Impact Training Improves Bone Mineral Density and Physical Function in Postmenopausal Women With Osteopenia and Osteoporosis: The LIFTMOR Randomized Controlled Trial: HEAVY LIFTING IMPROVES BMD IN OSTEOPOROSIS Efficacy of home-based exercise for improving quality of life among elderly women with symptomatic osteoporosis-related vertebral fractures Osteoporosis in the age of COVID-19 COVID-19 and osteoporosis Endocrinology in the time of COVID-19: Management of calcium disorders and osteoporosis Do we need sick-day guidelines for hypoparathyroidism? Indian